Barings Bdc (NYSE:BBDC) vs. Advanced Medical Isotope (OTCMKTS:RDGL) Head to Head Contrast

Barings Bdc (NYSE:BBDC) and Advanced Medical Isotope (OTCMKTS:RDGL) are both small-cap finance companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Barings Bdc and Advanced Medical Isotope’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Barings Bdc	36.50%	10.05%	4.27%
Advanced Medical Isotope	-6,144.90%	N/A	-113.56%

Valuation and Earnings

This table compares Barings Bdc and Advanced Medical Isotope”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barings Bdc	$279.21 million	3.13	$101.92 million	$0.97	8.59
Advanced Medical Isotope	$30,000.00	1,334.73	-$2.91 million	N/A	N/A

Barings Bdc has higher revenue and earnings than Advanced Medical Isotope.

Institutional and Insider Ownership

44.1% of Barings Bdc shares are held by institutional investors. 0.6% of Barings Bdc shares are held by company insiders. Comparatively, 18.5% of Advanced Medical Isotope shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Barings Bdc has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Advanced Medical Isotope has a beta of -0.64, meaning that its share price is 164% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Barings Bdc and Advanced Medical Isotope, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barings Bdc	0	2	2	0	2.50
Advanced Medical Isotope	0	0	0	0	0.00

Barings Bdc currently has a consensus price target of $9.67, suggesting a potential upside of 15.98%. Given Barings Bdc’s stronger consensus rating and higher probable upside, research analysts plainly believe Barings Bdc is more favorable than Advanced Medical Isotope.

Summary

Barings Bdc beats Advanced Medical Isotope on 10 of the 12 factors compared between the two stocks.

About Barings Bdc

Barings BDC, Inc. is a publicly traded, externally managed investment company that has elected to be treated as a business development company under the Investment Company Act of 1940. It seeks to invest primarily in senior secured loans, first lien debt, unitranche, second lien debt, subordinated debt, equity co-investments and senior secured private debt investments in private middle-market companies that operate across a wide range of industries. It specializes in mezzanine, leveraged buyouts, management buyouts, ESOPs, change of control transactions, acquisition financings, growth financing, and recapitalizations in lower middle market, mature, and later stage companies. It invests in manufacturing and distribution; business services and technology; transportation and logistics; consumer product and services. It invests in United States. It invests in companies with EBITDA of $10 million to $75 million, typically in private equity sponsor backed.

About Advanced Medical Isotope

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.